- Overview
- COVID-19
- COVID-19 Vaccine Information
- My First Appointment
- Advance Care Planning
- Patient Forms
- Patient Portal
- Make a Payment
- Health Plans
- FAQs
- Emergencies & After Hours
- Prescriptions
- Insurance Benefits & Financial Resources
- Patient Advocacy
- Resources & Support
- New Patient Orientation Classes
COVID-19
COVID19 Update:
If a person presents with a temperature, they will be asked to return home. Further instructions will be given by the health care team. No visitors are allowed in the infusion room. Telemedicine visits are available for routine office visits by request.
Message to All Patients, very important:
Regardless of vaccination status – If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and diarrhea, you should contact Shenandoah Oncology before visiting our clinic for any scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.
Effective May 11, 2023:
The federal Public Health Emergency (PHE) has expired. Shenandoah Oncology will adopt a mask optional policy. The health and safety of our patients and employees is always our top priority. If you prefer your healthcare team to wear a mask during your visit, please let us know. Additionally, Shenandoah Oncology may ask you to wear a mask during your visit.
Who is eligible to receive a single booster dose and when:
- Individuals 18 years of age and older are eligible for a single booster dose of the Moderna COVID-19 Vaccine, Bivalent, if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
- Individuals 12 years of age and older are eligible for a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
Persons receiving immunosuppressive therapies:
- Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies.
Learn More